Company News
Lipocine Shares Plunge 77% After Trial Miss
Lipocine Inc. shares plunged 77% after its phase‑3 postpartum‑depression drug LPCN 1154 missed the primary endpoint.
The trial of 90 patients showed no statistically significant HAM‑D17 score reductio
